Trials / Completed
CompletedNCT00549068
POWER Point of Care Effect on Satisfaction of Treatment
Impact of NTx Point of Care (POC) Device on Patient Satisfication With Actonel 35mg Once a Seek Treatment a Multicenter Prospective Open Label Randomized Controlled Community Practice-based Study
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 2,433 (actual)
- Sponsor
- Sanofi · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To compare the subject satisfaction rating in women treated for postmenopausal osteoporosis with Actonel 35mg Once-a-Week for 24 weeks, and receiving feedback information, after 12 weeks of treatment, based on bone resorption marker results using the NTx Point-Of-Care (POC) device, to similar women treated as per regular clinical practice
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Risedronate Sodium (Actonel) |
Timeline
- Start date
- 2003-02-01
- Completion
- 2004-11-01
- First posted
- 2007-10-25
- Last updated
- 2009-12-07
Source: ClinicalTrials.gov record NCT00549068. Inclusion in this directory is not an endorsement.